Trials / Terminated

TerminatedNCT04826224

CAM Procedure With BMAC for Shoulder OA

A Pilot Study For The Use Of Human Autologous Bone Marrow Aspirate Concentrate (BMAC) Combined With Arthroscopic Surgery For Painful Shoulder Osteoarthritis

Status: Terminated
Phase: Phase 1
Study type: Interventional
Enrollment: 2 (actual)

Sponsor: Shane A. Shapiro · Academic / Other
Sex: All
Age: 50 Years
Healthy volunteers: Not accepted

Summary

Researchers want to find out more about the side effects of Bone Marrow Aspirate Concentrate (BMAC) and what doses of BMAC are safe for people.

Conditions

Shoulder Osteoarthritis

Interventions

Type	Name	Description
BIOLOGICAL	Concentrated bone marrow aspirate administration after Comprehensive Arthroscopic Management (CAM) surgical procedure.	Bone marrow aspirate concentrate contains a median nucleated cell count of 121,700/uL, and platelets of 384,000/uL. This leads to a cellular dose of approximately 400 million cells.

Timeline

Start date: 2021-12-06
Primary completion: 2025-08-21
Completion: 2025-08-21
First posted: 2021-04-01
Last updated: 2026-01-20

Locations

1 site across 1 country: United States

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT04826224. Inclusion in this directory is not an endorsement.